Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle Vaccine

ABSTRACT There is currently no standardized serum bactericidal antibody (SBA) assay for evaluating immune responses to meningococcal outer membrane vesicle or protein vaccines. Four laboratories, Manchester Health Protection Agency (MC HPA), New Zealand Institute of Environmental Science and Research Limited (NZ ESR), Norwegian Institute of Public Health (NIPH), and Chiron Vaccines (Chiron), measured SBA titers in the same panel of human sera (n = 76) from laboratory staff (n = 21) vaccinated with MenBvac. Blood samples were collected prevaccination, prior to each of the three doses of MenBvac given at 6-week intervals, and 6 weeks following the third dose. Initial results showed a number of discrepancies in results between the four participating laboratories. The greatest effect on titers appeared to be due to differences among laboratories in the maintenance of the meningococcal serogroup B test strain, 44/76-SL. A repeat study was conducted using the same frozen isolate (meningococcal serogroup B test strain 44/76-SL), freshly distributed to all four laboratories. Using SBA titers from the tilt method for all samples, and using MC HPA as the comparator, the results were as follows for NZ ESR, NIPH, and Chiron, respectively, using log10 titers: correlation coefficients (r) were 0.966, 0.967, and 0.936; intercepts were 0.08, 0.15, and 0.17; and slopes were 0.930, 0.851, and 0.891. In both prevaccination and postvaccination samples from 15 subjects assayed by all four laboratories, similar increases in SBA (fourfold or greater) were observed (for 11, 11, 9, and 9 subjects for MC HPA, NZ ESR, NIPH, and Chiron, respectively), and similar percentages of subjects with SBA titers of ≥4 prevaccination and 6 weeks following each dose were found. The SBA assay has been harmonized between the four different laboratories with good agreement on seroconversion rates, n-fold changes in titers, and percentages of subjects with SBA titers of ≥4.

[1]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[2]  N. Andrews,et al.  Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. , 2003, Vaccine.

[3]  E. Rosenqvist,et al.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. , 2003, Vaccine.

[4]  J. Poolman,et al.  Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. , 1999, Vaccine.

[5]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[6]  B. Plikaytis,et al.  Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. , 1998, The Journal of infectious diseases.

[7]  M. Baker,et al.  New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. , 1998, The Journal of infectious diseases.

[8]  G. Carlone,et al.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group , 1997, Clinical and diagnostic laboratory immunology.

[9]  G. Carlone,et al.  Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays , 1997 .

[10]  E. Rosenqvist,et al.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine , 1995, Infection and immunity.

[11]  J. Boslego,et al.  Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. , 1995, Vaccine.

[12]  C. Sacchi,et al.  Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy , 1994, Infection and immunity.

[13]  M. Achtman,et al.  The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. , 1993, The Journal of infectious diseases.

[14]  M. H. Terry,et al.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. , 1991, NIPH annals.

[15]  E. Rosenqvist,et al.  Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. , 1991, NIPH annals.

[16]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.

[17]  I. Goldschneider,et al.  Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. , 1978, The Journal of infectious diseases.

[18]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[19]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .